;PMID: 11531932
;source_file_706.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..43] = [t:0..43]
;1)sentence:[e:48..114] = [t:48..114]
;2)section:[e:118..169] = [t:118..169]
;3)section:[e:173..237] = [t:173..237]
;4)sentence:[e:241..251] = [t:241..251]
;5)sentence:[e:252..384] = [t:252..384]
;6)sentence:[e:385..490] = [t:385..490]
;7)sentence:[e:491..641] = [t:491..641]
;8)sentence:[e:642..793] = [t:642..793]
;9)sentence:[e:794..801] = [t:794..801]
;10)sentence:[e:802..967] = [t:802..967]
;11)sentence:[e:968..1068] = [t:968..1068]
;12)sentence:[e:1069..1082] = [t:1069..1082]
;13)sentence:[e:1083..1146] = [t:1083..1146]
;14)sentence:[e:1147..1280] = [t:1147..1280]
;15)sentence:[e:1281..1480] = [t:1281..1480]
;16)sentence:[e:1481..1629] = [t:1481..1629]
;17)sentence:[e:1630..1638] = [t:1630..1638]
;18)sentence:[e:1639..1731] = [t:1639..1731]
;19)sentence:[e:1733..1821] = [t:1733..1821]
;20)sentence:[e:1822..1952] = [t:1822..1952]
;21)sentence:[e:1953..2010] = [t:1953..2010]
;22)sentence:[e:2011..2022] = [t:2011..2022]
;23)sentence:[e:2023..2236] = [t:2023..2236]
;24)section:[e:2240..2285] = [t:2240..2285]

;section 0 Span:0..43
;Clin Endocrinol (Oxf)  2001 Aug;55(2):241-8
(SEC
  (FRAG (JJ:[0..4] Clin) (NNS:[5..15] Endocrinol) (-LRB-:[16..17] -LRB-)
        (NN:[17..20] Oxf) (-RRB-:[20..21] -RRB-) (CD:[23..27] 2001)
        (CC:[28..35] Aug;55-LRB-) (CD:[35..36] 2) (-RRB-:[36..37] -RRB-)
        (CD:[37..41] :241) (::[41..42] -) (CD:[42..43] 8)))

;sentence 1 Span:48..114
;Ras mutations are rare in solitary cold and toxic thyroid nodules.
;[48..51]:gene-rna:"Ras"
;[74..87]:malignancy:"solitary cold"
;[92..113]:malignancy:"toxic thyroid nodules"
(SENT
  (S-HLN
    (NP-SBJ (NN:[48..51] Ras) (NNS:[52..61] mutations))
    (VP (VBP:[62..65] are)
      (ADJP-PRD (JJ:[66..70] rare))
      (PP-LOC (IN:[71..73] in)
        (NP (JJ:[74..82] solitary)
          (NML (JJ:[83..87] cold)
            (NML-1 (-NONE-:[87..87] *P*)))
          (CC:[88..91] and)
          (NML (JJ:[92..97] toxic) (JJ:[98..105] thyroid)
            (NML-1 (NNS:[106..113] nodules))))))
    (.:[113..114] .)))

;section 2 Span:118..169
;Krohn K, Reske A, Ackermann F, Muller A, Paschke R.
(SEC
  (FRAG (NNP:[118..123] Krohn) (NNP:[124..125] K) (,:[125..126] ,)
        (NNP:[127..132] Reske) (NNP:[133..134] A) (,:[134..135] ,)
        (NNP:[136..145] Ackermann) (NNP:[146..147] F) (,:[147..148] ,)
        (NNP:[149..155] Muller) (NNP:[156..157] A) (,:[157..158] ,)
        (NNP:[159..166] Paschke) (NNP:[167..169] R.)))

;section 3 Span:173..237
;III Medical Department, University of Leipzig, Leipzig, Germany.
(SEC
  (FRAG (NNP:[173..176] III) (NNP:[177..184] Medical)
        (NNP:[185..195] Department) (,:[195..196] ,) (NNP:[197..207] University)
        (IN:[208..210] of) (NNP:[211..218] Leipzig) (,:[218..219] ,)
        (NNP:[220..227] Leipzig) (,:[227..228] ,) (NNP:[229..236] Germany)
        (.:[236..237] .)))

;sentence 4 Span:241..251
;OBJECTIVE:
(SENT
  (NP (NN:[241..250] OBJECTIVE) (::[250..251] :)))

;sentence 5 Span:252..384
;Activation of ras proto-oncogenes as a result of point mutations is 
;detectable in a significant percentage of most types of tumour.
;[266..269]:gene-rna:"ras"
;[301..316]:variation-type:"point mutations"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[252..262] Activation))
      (PP (IN:[263..265] of)
        (NP (NN:[266..269] ras) (AFX:[270..275] proto) (HYPH:[275..276] -)
            (NNS:[276..285] oncogenes)))
      (PP (IN:[286..288] as)
        (NP
          (NP (DT:[289..290] a) (NN:[291..297] result))
          (PP (IN:[298..300] of)
            (NP (NN:[301..306] point) (NNS:[307..316] mutations))))))
    (VP (VBZ:[317..319] is)
      (ADJP-PRD (JJ:[321..331] detectable))
      (PP (IN:[332..334] in)
        (NP
          (NP (DT:[335..336] a) (JJ:[337..348] significant)
              (NN:[349..359] percentage))
          (PP (IN:[360..362] of)
            (NP
              (NP (DT:[363..367] most) (NNS:[368..373] types))
              (PP (IN:[374..376] of)
                (NP (NN:[377..383] tumour))))))))
    (.:[383..384] .)))

;sentence 6 Span:385..490
;Similar to  neoplasms of other organs, mutations of all three ras genes can
;be found in  thyroid tumours.
;[447..450]:gene-rna:"ras"
;[474..489]:malignancy:"thyroid tumours"
(SENT
  (S
    (S-ADV
      (NP-SBJ (-NONE-:[385..385] *))
      (ADJP-PRD (JJ:[385..392] Similar)
        (PP (TO:[393..395] to)
          (NP
            (NP (NN:[397..406] neoplasms))
            (PP (IN:[407..409] of)
              (NP (JJ:[410..415] other) (NNS:[416..422] organs)))))))
    (,:[422..423] ,)
    (NP-SBJ-1
      (NP (NNS:[424..433] mutations))
      (PP (IN:[434..436] of)
        (NP-SBJ (DT:[437..440] all) (CD:[441..446] three) (NN:[447..450] ras)
                (NNS:[451..456] genes))))
    (VP (MD:[457..460] can)
      (VP (VB:[461..463] be)
        (VP (VBN:[464..469] found)
          (NP-1 (-NONE-:[469..469] *))
          (PP-LOC (IN:[470..472] in)
            (NP (JJ:[474..481] thyroid) (NNS:[482..489] tumours))))))
    (.:[489..490] .)))

;sentence 7 Span:491..641
;H-, K- and N-ras mutations have been detected in up to 20% of  follicular
;adenomas and adenomatous nodules which were not functionally  characterized.
;[491..493]...[504..507]:gene-rna:"H-"..."ras"
;[495..497]...[504..507]:gene-rna:"K-"..."ras"
;[502..507]:gene-rna:"N-ras"
;[554..573]:malignancy:"follicular adenomas"
;[578..597]:malignancy:"adenomatous nodules"
(SENT
  (S
    (NP-SBJ-2
      (NP
        (NML (NN:[491..492] H) (HYPH:[492..493] -)
          (NML-4 (-NONE-:[493..493] *P*)))
        (NML-3 (-NONE-:[493..493] *P*)))
      (,:[493..494] ,)
      (NP
        (NML (NN:[495..496] K) (HYPH:[496..497] -)
          (NML-4 (-NONE-:[497..497] *P*)))
        (NML-3 (-NONE-:[497..497] *P*)))
      (CC:[498..501] and)
      (NP
        (NML (NN:[502..503] N) (HYPH:[503..504] -)
          (NML-4 (NN:[504..507] ras)))
        (NML-3 (NNS:[508..517] mutations))))
    (VP (VBP:[518..522] have)
      (VP (VBN:[523..527] been)
        (VP (VBN:[528..536] detected)
          (NP-2 (-NONE-:[536..536] *))
          (PP-LOC (IN:[537..539] in)
            (NP
              (NP
                (QP (IN:[540..542] up) (TO:[543..545] to) (CD:[546..548] 20))
                (NN:[548..549] %))
              (PP (IN:[550..552] of)
                (NP
                  (NP
                    (NP (JJ:[554..564] follicular) (NNS:[565..573] adenomas))
                    (CC:[574..577] and)
                    (NP (JJ:[578..589] adenomatous) (NNS:[590..597] nodules)))
                  (SBAR
                    (WHNP-1 (WDT:[598..603] which))
                    (S
                      (NP-SBJ-1 (-NONE-:[603..603] *T*))
                      (VP (VBD:[604..608] were) (RB:[609..612] not)
                        (ADVP (JJ:[613..625] functionally))
                        (VP (VBN:[627..640] characterized)
                          (NP-1 (-NONE-:[640..640] *)))))))))))))
    (.:[640..641] .)))

;sentence 8 Span:642..793
;This raises the question as to whether ras mutations are specific  for
;hypofunctional nodules and TSH receptor mutations for hyperfunctioning 
;nodules.
;[681..684]:gene-rna:"ras"
;[713..735]:malignancy:"hypofunctional nodules"
;[740..752]:gene-protein:"TSH receptor"
;[767..792]:malignancy:"hyperfunctioning  nodules"
(SENT
  (S
    (NP-SBJ (DT:[642..646] This))
    (VP (VBZ:[647..653] raises)
      (NP
        (NP (DT:[654..657] the) (NN:[658..666] question))
        (PP (IN:[667..669] as)
          (PP (TO:[670..672] to)
            (SBAR-NOM (IN:[673..680] whether)
              (S
                (S
                  (NP-SBJ=1 (NN:[681..684] ras) (NNS:[685..694] mutations))
                  (VP (VBP:[695..698] are)
                    (ADJP-PRD (JJ:[699..707] specific)
                      (PP (IN:[709..712] for)
                        (NP=2 (JJ:[713..727] hypofunctional)
                              (NNS:[728..735] nodules))))))
                (CC:[736..739] and)
                (S
                  (NP-SBJ=1
                    (NML (NN:[740..743] TSH) (NN:[744..752] receptor))
                    (NNS:[753..762] mutations))
                  (PP (IN:[763..766] for)
                    (NP=2 (VBG:[767..783] hyperfunctioning)
                          (NNS:[785..792] nodules))))))))))
    (.:[792..793] .)))

;sentence 9 Span:794..801
;DESIGN:
(SENT
  (NP (NN:[794..800] DESIGN) (::[800..801] :)))

;sentence 10 Span:802..967
;To investigate ras and TSH receptor mutations with respect to  functional
;differentiation we studied 41 scintigraphically cold nodules and 47  toxic
;thyroid nodules.
;[817..820]:gene-rna:"ras"
;[825..837]:gene-protein:"TSH receptor"
;[924..936]:malignancy:"cold nodules"
;[945..966]:malignancy:"toxic thyroid nodules"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[802..802] *))
      (VP (TO:[802..804] To)
        (VP (VB:[805..816] investigate)
          (NP
            (NP
              (NML (NN:[817..820] ras))
              (NML-2 (-NONE-:[820..820] *P*)))
            (CC:[821..824] and)
            (NP
              (NML (NN:[825..828] TSH) (NN:[829..837] receptor))
              (NML-2 (NNS:[838..847] mutations))))
          (PP (IN:[848..852] with)
            (NP
              (NP (NN:[853..860] respect))
              (PP (TO:[861..863] to)
                (NP (JJ:[865..875] functional) (NN:[876..891] differentiation))))))))
    (NP-SBJ (PRP:[892..894] we))
    (VP (VBD:[895..902] studied)
      (NP
        (NP (CD:[903..905] 41)
          (ADJP (RB:[906..923] scintigraphically) (JJ:[924..928] cold))
          (NNS:[929..936] nodules))
        (CC:[937..940] and)
        (NP (CD:[941..943] 47)
           (JJ:[945..950] toxic) (JJ:[951..958] thyroid)
           (NNS:[959..966] nodules))))
    (.:[966..967] .)))

;sentence 11 Span:968..1068
;To address the likelihood of a somatic mutation we also  studied the clonal
;origin of these tumours.
;[1060..1067]:malignancy:"tumours"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[968..968] *))
      (VP (TO:[968..970] To)
        (VP (VB:[971..978] address)
          (NP
            (NP (DT:[979..982] the) (NN:[983..993] likelihood))
            (PP (IN:[994..996] of)
              (NP (DT:[997..998] a) (JJ:[999..1006] somatic)
                  (NN:[1007..1015] mutation)))))))
    (NP-SBJ (PRP:[1016..1018] we))
    (VP
      (ADVP (RB:[1019..1023] also))
      (VBD:[1025..1032] studied)
      (NP
        (NP (DT:[1033..1036] the) (JJ:[1037..1043] clonal)
            (NN:[1044..1050] origin))
        (PP (IN:[1051..1053] of)
          (NP (DT:[1054..1059] these) (NNS:[1060..1067] tumours)))))
    (.:[1067..1068] .)))

;sentence 12 Span:1069..1082
;MEASUREMENTS:
(SENT
  (NP (NNS:[1069..1081] MEASUREMENTS) (::[1081..1082] :)))

;sentence 13 Span:1083..1146
;Genomic DNA was  extracted from nodular and surrounding tissue.
;[1115..1122]:malignancy:"nodular"
(SENT
  (S
    (NP-SBJ-2 (JJ:[1083..1090] Genomic) (NN:[1091..1094] DNA))
    (VP (VBD:[1095..1098] was)
      (VP (VBN:[1100..1109] extracted)
        (NP-2 (-NONE-:[1109..1109] *))
        (PP-CLR (IN:[1110..1114] from)
          (NP
            (NP (JJ:[1115..1122] nodular)
              (NML-1 (-NONE-:[1122..1122] *P*)))
            (CC:[1123..1126] and)
            (NP (JJ:[1127..1138] surrounding)
              (NML-1 (NN:[1139..1145] tissue)))))))
    (.:[1145..1146] .)))

;sentence 14 Span:1147..1280
;Mutational hot spots in exons 1  and 2 of the H- and K-ras gene were PCR
;amplified and sequenced using big dye  terminator chemistry.
;[1171..1178]:variation-location:"exons 1"
;[1171..1176]...[1184..1185]:variation-location:"exons"..."2"
;[1193..1195]...[1202..1205]:gene-rna:"H-"..."ras"
;[1200..1205]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[1147..1157] Mutational) (JJ:[1158..1161] hot)
          (NNS:[1162..1167] spots))
      (PP-LOC (IN:[1168..1170] in)
        (NP
          (NP
            (NP
              (NML-4 (NNS:[1171..1176] exons))
              (CD:[1177..1178] 1))
            (CC:[1180..1183] and)
            (NP
              (NML-4 (-NONE-:[1183..1183] *P*))
              (CD:[1184..1185] 2)))
          (PP (IN:[1186..1188] of)
            (NP (DT:[1189..1192] the)
              (NML
                (NML
                  (NML (NN:[1193..1194] H) (HYPH:[1194..1195] -)
                    (NML-2 (-NONE-:[1195..1195] *P*)))
                  (NML-3 (-NONE-:[1195..1195] *P*)))
                (CC:[1196..1199] and)
                (NML
                  (NML (NN:[1200..1201] K) (HYPH:[1201..1202] -)
                    (NML-2 (NN:[1202..1205] ras)))
                  (NML-3 (NN:[1206..1210] gene)))))))))
    (VP
      (VP (VBD:[1211..1215] were)
        (VP (NN:[1216..1219] PCR) (VBN:[1220..1229] amplified)
          (NP-1 (-NONE-:[1229..1229] *))))
      (CC:[1230..1233] and)
      (VP (VBN:[1234..1243] sequenced)
        (NP-1 (-NONE-:[1243..1243] *))
        (S-PRP
          (NP-SBJ (-NONE-:[1243..1243] *))
          (VP (VBG:[1244..1249] using)
            (NP
              (NML
                (NML (JJ:[1250..1253] big) (NN:[1254..1257] dye))
                (NN:[1259..1269] terminator))
              (NN:[1270..1279] chemistry))))))
    (.:[1279..1280] .)))

;sentence 15 Span:1281..1480
;Denaturing gradient gel electrophoresis (DGGE) was used to  verify sequencing
;results for the H-ras gene and to analyse the N-ras gene  because its greater
;sensitivity in detecting somatic mutations.
;[1375..1380]:gene-rna:"H-ras"
;[1405..1410]:gene-rna:"N-ras"
(SENT
  (S
    (NP-SBJ-1
      (NP (VBG:[1281..1291] Denaturing) (NN:[1292..1300] gradient)
          (NN:[1301..1304] gel) (NN:[1305..1320] electrophoresis))
      (NP (-LRB-:[1321..1322] -LRB-) (NN:[1322..1326] DGGE)
          (-RRB-:[1326..1327] -RRB-)))
    (VP (VBD:[1328..1331] was)
      (VP (VBN:[1332..1336] used)
        (NP-1 (-NONE-:[1336..1336] *))
        (S-ADV
          (NP-SBJ (-NONE-:[1336..1336] *))
          (VP (TO:[1337..1339] to)
            (VP
              (VP (VB:[1341..1347] verify)
                (NP
                  (NP (NN:[1348..1358] sequencing) (NNS:[1359..1366] results))
                  (PP (IN:[1367..1370] for)
                    (NP (DT:[1371..1374] the) (NN:[1375..1380] H-ras)
                        (NN:[1381..1385] gene)))))
              (CC:[1386..1389] and)
              (VP (TO:[1390..1392] to)
                (VP (VB:[1393..1400] analyse)
                  (NP (DT:[1401..1404] the) (NN:[1405..1410] N-ras)
                      (NN:[1411..1415] gene)))))))
        (PP (IN:[1417..1424] because)
          (NP
            (NP (PRP$:[1425..1428] its) (JJR:[1429..1436] greater)
                (NN:[1437..1448] sensitivity))
            (PP (IN:[1449..1451] in)
              (S-NOM
                (NP-SBJ (-NONE-:[1451..1451] *))
                (VP (VBG:[1452..1461] detecting)
                  (NP (JJ:[1462..1469] somatic) (NNS:[1470..1479] mutations)))))))))
    (.:[1479..1480] .)))

;sentence 16 Span:1481..1629
;Clonality of  nodular thyroid tissue was evaluated using X-Chromosome
;inactivation based on  PCR amplification of the human androgen receptor
;locus.
;[1495..1517]:malignancy:"nodular thyroid tissue"
;[1599..1622]:gene-protein:"human androgen receptor"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[1481..1490] Clonality))
      (PP (IN:[1491..1493] of)
        (NP (JJ:[1495..1502] nodular) (JJ:[1503..1510] thyroid)
            (NN:[1511..1517] tissue))))
    (VP (VBD:[1518..1521] was)
      (VP (VBN:[1522..1531] evaluated)
        (NP-1 (-NONE-:[1531..1531] *))
        (S-MNR
          (NP-SBJ (-NONE-:[1531..1531] *))
          (VP (VBG:[1532..1537] using)
            (NP
              (NP
                (NML (NN:[1538..1539] X) (HYPH:[1539..1540] -)
                     (NN:[1540..1550] Chromosome))
                (NN:[1551..1563] inactivation))
              (VP (VBN:[1564..1569] based)
                (NP (-NONE-:[1569..1569] *))
                (PP-CLR (IN:[1570..1572] on)
                  (NP
                    (NP (NN:[1574..1577] PCR) (NN:[1578..1591] amplification))
                    (PP (IN:[1592..1594] of)
                      (NP (DT:[1595..1598] the)
                         (JJ:[1599..1604] human)
                        (NML (NN:[1605..1613] androgen)
                             (NN:[1614..1622] receptor))
                        (NN:[1623..1628] locus)))))))))))
    (.:[1628..1629] .)))

;sentence 17 Span:1630..1638
;RESULTS:
(SENT
  (NP (NNS:[1630..1637] RESULTS) (::[1637..1638] :)))

;sentence 18 Span:1639..1731
;Monoclonal  origin was detectable in 14 of 23 informative samples from cold
;thyroid nodules.
;[1710..1730]:malignancy:"cold thyroid nodules"
(SENT
  (S
    (NP-SBJ (JJ:[1639..1649] Monoclonal) (NN:[1651..1657] origin))
    (VP (VBD:[1658..1661] was)
      (ADJP-PRD (JJ:[1662..1672] detectable))
      (PP-LOC (IN:[1673..1675] in)
        (NP
          (NP (CD:[1676..1678] 14))
          (PP (IN:[1679..1681] of)
            (NP
              (NP (CD:[1682..1684] 23) (JJ:[1685..1696] informative)
                  (NNS:[1697..1704] samples))
              (PP (IN:[1705..1709] from)
                (NP (JJ:[1710..1714] cold) (JJ:[1715..1722] thyroid)
                    (NNS:[1723..1730] nodules))))))))
    (.:[1730..1731] .)))

;sentence 19 Span:1733..1821
;In toxic thyroid nodules the frequency of clonal tissue was 20 in 30
;informative  cases.
;[1736..1757]:malignancy:"toxic thyroid nodules"
(SENT
  (S
    (PP (IN:[1733..1735] In)
      (NP (JJ:[1736..1741] toxic) (JJ:[1742..1749] thyroid)
          (NNS:[1750..1757] nodules)))
    (NP-SBJ
      (NP (DT:[1758..1761] the) (NN:[1762..1771] frequency))
      (PP (IN:[1772..1774] of)
        (NP (JJ:[1775..1781] clonal) (NN:[1782..1788] tissue))))
    (VP (VBD:[1789..1792] was)
      (NP-PRD
        (NP (CD:[1793..1795] 20))
        (PP (IN:[1796..1798] in)
          (NP (CD:[1799..1801] 30) (JJ:[1802..1813] informative)
              (NNS:[1815..1820] cases)))))
    (.:[1820..1821] .)))

;sentence 20 Span:1822..1952
;Only one point mutation could be found in the N-ras gene codon 61 (Gly to 
;Arg) in a cold adenomatous nodule which was monoclonal.
;[1831..1845]:variation-type:"point mutation"
;[1868..1873]:gene-rna:"N-ras"
;[1879..1887]:variation-location:"codon 61"
;[1889..1892]:variation-state-original:"Gly"
;[1897..1900]:variation-state-altered:"Arg"
;[1907..1930]:malignancy:"cold adenomatous nodule"
(SENT
  (S
    (NP-SBJ-2 (RB:[1822..1826] Only) (CD:[1827..1830] one)
       (NN:[1831..1836] point) (NN:[1837..1845] mutation))
    (VP (MD:[1846..1851] could)
      (VP (VB:[1852..1854] be)
        (VP (VBN:[1855..1860] found)
          (NP-2 (-NONE-:[1860..1860] *))
          (PP-LOC (IN:[1861..1863] in)
            (NP
              (NP (DT:[1864..1867] the)
                (NML (NN:[1868..1873] N-ras) (NN:[1874..1878] gene))
                 (NN:[1879..1884] codon) (CD:[1885..1887] 61)
                (PRN (-LRB-:[1888..1889] -LRB-)
                  (NP
                    (NP (NN:[1889..1892] Gly))
                    (PP (TO:[1893..1895] to)
                      (NP (NN:[1897..1900] Arg))))
                  (-RRB-:[1900..1901] -RRB-)))
              (PP-LOC (IN:[1902..1904] in)
                (NP
                  (NP (DT:[1905..1906] a)
                     (JJ:[1907..1911] cold) (JJ:[1912..1923] adenomatous)
                     (NN:[1924..1930] nodule))
                  (SBAR
                    (WHNP-1 (WDT:[1931..1936] which))
                    (S
                      (NP-SBJ-1 (-NONE-:[1936..1936] *T*))
                      (VP (VBD:[1937..1940] was)
                        (ADJP-PRD (JJ:[1941..1951] monoclonal))))))))))))
    (.:[1951..1952] .)))

;sentence 21 Span:1953..2010
;In toxic thyroid nodules  no ras mutation was detectable.
;[1956..1977]:malignancy:"toxic thyroid nodules"
;[1982..1985]:gene-rna:"ras"
;[1986..1994]:variation-event:"mutation"
(SENT
  (S
    (PP (IN:[1953..1955] In)
      (NP (JJ:[1956..1961] toxic) (JJ:[1962..1969] thyroid)
          (NNS:[1970..1977] nodules)))
    (NP-SBJ (DT:[1979..1981] no) (NN:[1982..1985] ras)
            (NN:[1986..1994] mutation))
    (VP (VBD:[1995..1998] was)
      (ADJP-PRD (JJ:[1999..2009] detectable)))
    (.:[2009..2010] .)))

;sentence 22 Span:2011..2022
;CONCLUSION:
(SENT
  (NP (NN:[2011..2021] CONCLUSION) (::[2021..2022] :)))

;sentence 23 Span:2023..2236
;Our study suggests that ras  mutations are rare in solitary cold and toxic
;thyroid nodules and that the  frequent monoclonal origin of these tumours
;implies somatic mutations in genes  other than H-, K- and N-ras.
;[2047..2050]:gene-rna:"ras"
;[2074..2087]:malignancy:"solitary cold"
;[2092..2113]:malignancy:"toxic thyroid nodules"
;[2164..2171]:malignancy:"tumours"
;[2219..2221]...[2232..2235]:gene-rna:"H-"..."ras"
;[2223..2225]...[2232..2235]:gene-rna:"K-"..."ras"
;[2230..2235]:gene-rna:"N-ras"
(SENT
  (S
    (NP-SBJ (PRP$:[2023..2026] Our) (NN:[2027..2032] study))
    (VP (VBZ:[2033..2041] suggests)
      (SBAR
        (SBAR (IN:[2042..2046] that)
          (S
            (NP-SBJ (NN:[2047..2050] ras) (NNS:[2052..2061] mutations))
            (VP (VBP:[2062..2065] are)
              (ADJP-PRD (JJ:[2066..2070] rare))
              (PP-LOC (IN:[2071..2073] in)
                (NP (JJ:[2074..2082] solitary)
                  (NML
                    (NML (JJ:[2083..2087] cold)
                      (NML-2 (-NONE-:[2087..2087] *P*)))
                    (CC:[2088..2091] and)
                    (NML (JJ:[2092..2097] toxic) (JJ:[2098..2105] thyroid)
                      (NML-2 (NNS:[2106..2113] nodules)))))))))
        (CC:[2114..2117] and)
        (SBAR (IN:[2118..2122] that)
          (S
            (NP-SBJ
              (NP (DT:[2123..2126] the) (JJ:[2128..2136] frequent)
                  (JJ:[2137..2147] monoclonal) (NN:[2148..2154] origin))
              (PP (IN:[2155..2157] of)
                (NP (DT:[2158..2163] these) (NNS:[2164..2171] tumours))))
            (VP (VBZ:[2172..2179] implies)
              (NP
                (NP (JJ:[2180..2187] somatic) (NNS:[2188..2197] mutations))
                (PP-LOC (IN:[2198..2200] in)
                  (NP
                    (NP (NNS:[2201..2206] genes))
                    (ADJP
                      (ADJP (JJ:[2208..2213] other))
                      (PP (IN:[2214..2218] than)
                        (NP
                          (NP (NN:[2219..2220] H) (HYPH:[2220..2221] -)
                            (NML-1 (-NONE-:[2221..2221] *P*)))
                          (,:[2221..2222] ,)
                          (NP (NN:[2223..2224] K) (HYPH:[2224..2225] -)
                            (NML-1 (-NONE-:[2225..2225] *P*)))
                          (CC:[2226..2229] and)
                          (NP (NN:[2230..2231] N) (HYPH:[2231..2232] -)
                            (NML-1 (NN:[2232..2235] ras))))))))))))))
    (.:[2235..2236] .)))

;section 24 Span:2240..2285
;PMID: 11531932 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2240..2244] PMID) (::[2244..2245] :) (CD:[2246..2254] 11531932)
        (NN:[2255..2256] -LSB-) (NNP:[2256..2262] PubMed) (::[2263..2264] -)
        (NN:[2265..2272] indexed) (IN:[2273..2276] for)
        (NNP:[2277..2285] MEDLINE-RSB-)))
